华大基因: 第四届监事会第六次会议决议公告

Group 1 - The supervisory board of BGI Genomics confirmed the legality and compliance of the procedures for preparing and reviewing the 2025 semi-annual report, stating that the report accurately reflects the company's operational status without any false records or omissions [1][2]. - The supervisory board approved a capital increase of 22 million Saudi Riyals (approximately 42 million RMB) by its wholly-owned subsidiary BGI Almanahil to its associate company Genalive Medical Company, which will raise Genalive's registered capital from 90.5 million to 134.5 million Saudi Riyals [2][3]. - The board concluded that the capital increase is necessary for Genalive's business development and complies with relevant laws and regulations, ensuring fair pricing in the related transactions without harming the interests of the company or its shareholders [2][3]. Group 2 - The decision regarding the capital increase was unanimously approved with 3 votes in favor, and there were no votes against or abstentions [2][3]. - The announcement regarding the capital increase and related transactions was disclosed on the official information platform [3].